4.5 Article

Pilot study on sex hormone levels and fertility in women with malignant gliomas

期刊

JOURNAL OF NEURO-ONCOLOGY
卷 107, 期 2, 页码 387-394

出版社

SPRINGER
DOI: 10.1007/s11060-011-0761-8

关键词

Glioblastoma; Anaplastic astrocytomas; Endocrine deficiency; Quality of life

向作者/读者索取更多资源

The standard treatment of patients with high-grade gliomas based on conformal radiation therapy (RT) with or without chemotherapy (CT) may induce endocrine deficiencies of pituitary and subsequently also of peripheral hormones. In 24 premenopausal women with high-grade gliomas treated with RT and CT, hormonal changes and their impact on quality of life were investigated. Serum concentrations of gonadal, pituitary and of thyroid hormones were measured at various time points after initial anti-neoplastic therapy. Additionally, endovaginal ultrasound was performed and patients' quality of life (QLQ) and female role functioning were assessed. Of 24 patients, 23 (96%) reported a change in their menstrual pattern. Twenty-one patients reported at least transient amenorrhoea with a mean duration of 26.1 months (3-96 months). Increased prolactin serum levels were found in 10 women, 8 of them with amenorrhoea. Thirteen women showed menopausal or perimenopausal hormone pattern, 3 a pattern compatible with hypogonadism. Changes in thyroid hormone levels were seen in 8 patients. Furthermore, patients complained about fatigue and menopausal symptoms, like flushes, weakness and gain of weight. They felt a decrease of libido combined with the loss of attractiveness as a female, and an increased need for tender care and security. The hormonal deficiencies in female patients with malignant gliomas require thorough evaluation and individualized diagnosis and sometimes intervention.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial

Andrew B. Lassman, Stephanie L. Pugh, Tony J. C. Wang, Kenneth Aldape, Hui K. Gan, Matthias Preusser, Michael A. Vogelbaum, Erik P. Sulman, Minhee Won, Peixin Zhang, Golnaz Moazami, Marian S. Macsai, Mark R. Gilbert, Earle E. Bain, Vincent Blot, Peter J. Ansell, Suvajit Samanta, Madan G. Kundu, Terri S. Armstrong, Jeffrey S. Wefel, Clemens Seidel, Filip Y. de Vos, Sigmund Hsu, Andres F. Cardona, Giuseppe Lombardi, Dmitry Bentsion, Richard A. Peterson, Craig Gedye, Veronique Bourg, Antje Wick, Walter J. Curran, Minesh P. Mehta

Summary: The use of depatux-m in newly diagnosed glioblastomas (GBMs) with epidermal growth factor receptor gene amplification (EGFR-amp) did not improve overall survival (OS), but showed a longer progression-free survival. There were safety risks associated with the treatment, leading to treatment discontinuation for some patients.

NEURO-ONCOLOGY (2023)

Article Oncology

European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)

Khe Hoang-Xuan, Martina Deckert, Andres J. M. Ferreri, Julia Furtner, Jaime Gallego Perez-Larraya, Roger Henriksson, Andreas F. Hottinger, Benjamin Kasenda, Florence Lefranc, Alexander Lossos, Catherine McBain, Matthias Preusser, Patrick Roth, Roberta Ruda, Uwe Schlegel, Riccardo Soffietti, Carole Soussain, Martin J. B. Taphoorn, Valerie Touitou, Michael Weller, Jacoline E. C. Bromberg

Summary: The management of primary central nervous system lymphoma (PCNSL) is a controversial topic in neuro-oncology. The European Association of Neuro-Oncology (EANO) formed a multidisciplinary task force to update the evidence-based guidelines and include immunosuppressed patients. The guideline provides consensus considerations and recommendations for the treatment of PCNSL, including intraocular manifestations and specific management of the elderly.

NEURO-ONCOLOGY (2023)

Article Oncology

Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101

Emilie Le Rhun, Felix Boakye Oppong, Martin van den Bent, Wolfgang Wick, Alba A. Brandes, Martin J. B. Taphoorn, Michael Platten, Ahmed Idbaih, Paul M. Clement, Matthias Preusser, Vassilis Golfinopoulos, Thierry Gorlia, Michael Weller

Summary: This study retrospectively analyzed the incidence of lomustine-induced thrombocytopenia and its impact on treatment exposure and survival in patients with recurrent glioblastoma. The results showed that thrombocytopenia induced by lomustine is a major limitation to adequate exposure to lomustine chemotherapy and is associated with inferior progression-free survival, particularly in patients with MGMT promoter-methylated tumors.

EUROPEAN JOURNAL OF CANCER (2023)

Review Oncology

Emerging systemic treatment options in meningioma

Maximilian J. Mair, Anna S. Berghoff, Priscilla K. Brastianos, Matthias Preusser

Summary: Meningiomas are the most frequently diagnosed intracranial neoplasms and surgical resection is the common treatment method. However, there is limited research on pharmacotherapy for meningiomas.

JOURNAL OF NEURO-ONCOLOGY (2023)

Article Oncology

Comprehensive molecular profiling of sarcomas in adolescent and young adult patients: Results of the EORTC SPECTA-AYA international proof-of-concept study

Marie Morfouace, Peter Horak, Simon Kreutzfeldt, Aleksandra Stevovic, Teresa de Rojas, Evgeniya Denisova, Barbara Hutter, Francisco Bautista, Anne -Sophie Defachelles, Jeff White, Julio Oliveira, Bernd Kasper, Matthias Preusser, Vassilis Golfinopoulos, Stefan Pfister, Winette Van der Graaf, Eva Wardelmann, Patrick Shenjere, Stefan Froehling, Martin G. McCabe

EUROPEAN JOURNAL OF CANCER (2023)

Article Oncology

EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection

David Capper, Guido Reifenberger, Pim J. French, Leonille Schweizer, Michael Weller, Mehdi Touat, Simone P. Niclou, Philipp Euskirchen, Christine Haberler, Monika E. Hegi, Sebastian Brandner, Emilie Le Rhun, Roberta Ruda, Marc Sanson, Ghazaleh Tabatabai, Felix Sahm, Patrick Y. Wen, Pieter Wesseling, Matthias Preusser, Martin J. van den Bent

Summary: The mainstay of treatment for adult patients with gliomas, glioneuronal and neuronal tumors consists of combinations of surgery, radiotherapy, and chemotherapy. For many systemic cancers, targeted treatments are a part of the standard of care, however, the predictive significance of most of these targets in central nervous system (CNS) tumors remains less well-studied.

NEURO-ONCOLOGY (2023)

Editorial Material Oncology

Autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) in glioblastoma: Breakthrough or fata morgana?

Matthias Preusser, Martin J. van den Bent

NEURO-ONCOLOGY (2023)

Article Oncology

Brain metastases from hepatopancreatobiliary malignancies

Elisabeth S. Bergen, Alexander Friedrich, Peter Scherleitner, Pedro Ferreira, Barbara Kiesel, Georg Widhalm, Barbara Kiesewetter, Franziska Eckert, Gerald W. Prager, Matthias Preusser, Anna S. Berghoff

Summary: The prognosis of brain metastases from hepatopancreatobiliary tumors is very limited, with poor outcomes. Negative prognostic factors identified include performance status, age, and leptomeningeal carcinomatosis.

CLINICAL & EXPERIMENTAL METASTASIS (2023)

Review Oncology

Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline

Felix Sahm, Sebastian Brandner, Luca Bertero, David Capper, Pim J. French, Dominique Figarella-Branger, Felice Giangaspero, Christine Haberler, Monika E. Hegi, Bjarne W. Kristensen, Kathreena M. Kurian, Matthias Preusser, Bastiaan B. J. Tops, Martin van den Bent, Wolfgang Wick, Guido Reifenberger, Pieter Wesseling

Summary: In the 5th edition of the WHO CNS tumor classification, molecular characteristics have become important diagnostic criteria for many CNS tumor types. This guideline focuses on the methods used for diagnosing gliomas, glioneuronal, and neuronal tumors using informative molecular markers. Various molecular methods are discussed, including next-generation sequencing, methylation profiling, and immunohistochemistry. The guideline also covers the analysis of MGMT promoter methylation status, and provides an overview of the advantages, limitations, and requirements of different assays. The importance of molecular diagnostic testing in neuro-oncology is emphasized, along with discussions on clinical relevance, accessibility, cost, and ethical aspects.

NEURO-ONCOLOGY (2023)

Article Medicine, General & Internal

Screening for colorectal cancer A recommendation statement of the Austrian National Committee for Cancer Screening

Gerald Gartlehner, Eva Schernhammer, Sigurd F. Lax, Matthias Preusser, Herbert Bachler, Harald Tietzer, Maria Kletecka-Pulker, Helga Turnher, Uwe Siebert

Summary: Colorectal cancer screening in Austria is currently opportunistic and the Austrian National Committee for Cancer Screening has developed evidence-based recommendations for an organized nationwide screening program. The recommendations suggest that adults aged 45-75 should undergo either a 10-year screening colonoscopy or biennial fecal immunochemical tests. Screening decisions for individuals aged 65 and older should be based on their overall health, prior screening history, and preferences.

WIENER KLINISCHE WOCHENSCHRIFT (2023)

Article Oncology

Prophylactic treatment with oral azithromycin in cancer patients during the COVID-19 pandemic (OnCoVID): a randomized, single-blinded, placebo-controlled phase 2 trial

Maximilian J. Mair, Agnieszka Maj-Hes, Alina Nussbaumer-Proell, Rainer Puhr, Agnieszka Christenheit, Marlene Troch, Hannah C. Puhr, Angelika M. Starzer, Ariane Steindl, Sabine Eberl, Helmuth Haslacher, Thomas Perkmann, Christoph Minichsdorfer, Gerald W. Prager, Wolfgang W. Lamm, Anna S. Berghoff, Barbara Kiesewetter, Markus Zeitlinger, Matthias Preusser, Markus Raderer

Summary: This study aimed to investigate the preventive effect of azithromycin on COVID-19 infection in cancer patients, but due to low acceptance and low incidence of infection, the study was prematurely closed. Nevertheless, azithromycin had a favorable side effect profile in cancer patients.

INFECTIOUS AGENTS AND CANCER (2023)

Editorial Material Oncology

What is an isocitrate dehydrogenase-mutated central nervous system World Health Organization grade 2 glioma, or who should receive vorasidenib?

Matthias Preusser, Marjolein Geurts, Johannes A. Hainfellner, Martin J. van den Bent

NEURO-ONCOLOGY (2023)

Correction Medicine, General & Internal

Screening for colorectal cancer (May, 10.1007/s00508-023-02209-0, 2023)

Gerald Gartlehner, Eva Schernhammer, Sigurd F. Lax, Matthias Preusser, Herbert Bachler, Harald Titzer, Maria Kletecka-Pulker, Helga Turnher, Uwe Siebert

WIENER KLINISCHE WOCHENSCHRIFT (2023)

Article Oncology

Prognosticators of survival in patients with metastatic pancreatic cancer and ascites

J. M. Berger, A. Alany, L. Berchtold, R. Puhr, A. Friedrich, B. Scheiner, G. W. Prager, M. Preusser, A. S. Berghoff, E. S. Bergen

Summary: This study identified liver and peritoneal metastases as well as portal vein obstruction as prognostic factors after ascites diagnosis in metastatic pancreatic cancer patients. Continuation of systemic therapy after ascites diagnosis was associated with longer overall survival.

ESMO OPEN (2023)

Article Hematology

Growth differentiation factor-15 and prediction of cancer-associated thrombosis and mortality: a prospective cohort study

Stephan Nopp, Florian Moik, Simon Kraler, Cornelia Englisch, Matthias Preusser, Arnold von Eckardstein, Ingrid Pabinger, Thomas F. Luescher, Cihan Ay

Summary: GDF-15 is strongly associated with survival in cancer patients, independent of established risk factors. Although an association was identified with ATE and VTE in univariable analysis, GDF-15 was not independently associated with these outcomes and failed to improve established VTE prediction models.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2023)

暂无数据